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The skin is the first line of defense against environmental or microbial pathogens. A 
deviation of the skin barrier homeostasis by any kind of insult can result in an inflammatory 
response. The inflammatory response in turn can promote the development of an 
eczemaincluding atopic eczema. Thymic stromal lymphopoietin (TSLP) due to its pleiotropic 
nature play an important role in inflammatory disorders. 
The major aim of this thesis was to better understand the underlying mechanisms of TSLP 
production in the context of skin irritation and mast cell (MC) mediators and their 
contribution in the development of atopic dermatitis (AD). The role of TSLP was studied 
using TSLPR-/- mice. The data show that TSLPR-/- and TNF-/-/TSLPR-/- mice were 
protected from AD development, by contrast TNF-/- mice exhibited severe AD. The role of 
exogenous triggers was studied using tape stripping mediated skin irritation mouse models. 
Skin irritation resulted in significant enhanced TSLP production. TSLP induction was 
identified to depend on interleukin (IL)-1 and protease activated receptor (PAR)-2 pathways 
proven by using exogenous activators or inhibitors of these pathways. Moreover, PAR-2 and 
IL-1 concomitantly promoted NF-κB binding to the human TSLP promoter which in turn 
resulted in an increased TSLP promoter activity. Additionally, the role of mast cell mediators 
in the context of TSLP induction was investigated. Tryptase turned out to be the trigger 
responsible for the enhanced TSLP response by activating the PAR-2 pathway. This finding 
was proven by employing in vitro, ex vivo and in vivo approaches. In detail PAR-2-/- and 
MC-/- mice were used in a compound 48/80 (C48/80) dependent MCs degranulation model. 
PAR-2-/- and MC-/- mice produced significantly less TSLP in comparison to control mice. 
Finally, these observations were confirmed in human primary keratinocytes (KCs) were 
tryptase and IL-1 mediated activation of the PAR-2 pathway in concert with the IL-1 pathway 
to elicit TSLP production.           
 
Schlagwörter:  Thymic stromal lymphopoietin, Hauterkrankungen, Atopischen Dermatitis, 
Mastzellen, Interleukin-1 







Die Haut ist das größte Organ des Menschen und stellt die primäre Barriere gegen 
Umwelteinflüsse und Pathogene dar. Eine Dysbalance der Hautbarriere birgt die Gefahr einer 
nachfolgenden Entzündungsreaktion. Bleibt diese bestehen, können sich Hautkrankheiten wie 
zum Beispiel die atopische Dermatitis (AD) entwickeln. Verschiedene Zytokine wie Thymic 
Stromal Lymphopoietin (TSLP) werden bei entzündlichen Hauterkrankungen eine 
bedeutende Rolle zugeschrieben.  
Hauptziel der vorliegenden Arbeit war die Aufklärung von Mechanismen, die durch 
Hautirritation ausgelöst oder durch Mastzellmediatoren zu einem Anstieg von TSLP als 
Wegbereiter einer Entzündungsreaktion in der Haut stattfinden.  
Die Bedeutung von TSLP wurde zunächst anhand mehrerer Knockout-Mausstämme 
untersucht. Hier zeigte sich, dass TSLPR-KO und TNF-TSLPR-DKO Mäuse im Gegensatz 
zu TNF-KO Mäusen keine bzw. weniger Zeichen einer Entzündungsreaktion in der Haut 
entwickeln. Die Rolle äußerer Einflüsse auf die TSLP-Produktion wurde anhand eines 
Irritationsmodells ebenfalls in Mäusen untersucht. Dabei führte die Hautirritation, ausgelöst 
durch Abtragen der oberen Hautschichten mittels eines Tesa-Abriss, zu einem signifikanten 
Anstieg von TSLP in der Haut?. Mit Hilfe von Agonisten und Inhibitoren konnte gezeigt 
werden, dass dieser Irritations-vermittelte TSLP-Anstieg über Interleukin-1 (IL-1) und 
Protease Activated Receptor 2 (PAR-2) vermittelt wird. In diesem Zusammenhang wurde 
auch gezeigt, dass die Aktivierung von IL-1- sowie PAR-2-abhängigen Signalwegen zu einer 
gesteigerten Aktivität des TSLP-Promotors führte.  
Die Untersuchung der Wirkung verschiedener Mastzellmediatoren auf die TSLP-Expression 
ergab, dass Tryptase, über die Aktivierung von PAR-2, der wichtigste Mediator für den 
Anstieg von TSLP nach der Degranulation von Mastzellen ist. Dieses Ergebnis wurde mittels 
verschiedener in vitro, in vivo und ex vivo Experimentalansätze belegt. So konnte in einem 
c48/80-abhängigen Degranulationsmodell in Mäusen gezeigt werden, dss PAR-2- sowie 
Mastzell-KO Mäuse im Vergleich zu Wildtypen nach Injektion von c48/80 signifikant 
weniger TSLP exprimierten. Abschließend konnte das Zusammenspiel von PAR-2- und IL-1-
vermittelten Signalwegen in Bezug auf TSLP in humanen Keratinozyten bestätigt werden.  
Schlagwörter:  Thymic stromal lymphopoietin, Hauterkrankungen, Atopischen Dermatitis, 
Mastzellen, Interleukin-1 











1.1 SKIN STRUCTURE 
The skin acts as a protective barrier and protects the body from a wide range of potential 
harmful pathogens by separating inner and outer environment.1 The skin is built of three 
layers, the outer epidermis, the dermis and the subcutis respectively.2 The epidermis is of 
utmost relevance for the barrier integrity of the skin and confers the body with physical, 
chemical or biochemical protections. The epidermis consists of various layers of 
keratinocytes which go through the process of differentiation. These are the innermost 
stratum basale, the stratum spinosum, the stratum granulosum and upper most the stratum 
corneum.1,3,4 The stratum basale layer contains basal stem cells, which are capable of 
proliferation to generate keratinocytes and can expand the cell numbers.5 The stratum 
spinosum is defined by evident desmosomes, which help the appearance of spindle shaped 
cells. Early differentiation marker cytokeratin 10 is expressed by the cells of this layer. 
Differentiation of cells can be seen from bottom to top by the visibility of involucrin, an 
intermediate differentiation marker, in upper cell lyers but not in the lower spinous cell 
layers. The center part of the skin mainly consists of flat anucleated corneocytes. These 
anucleated cells contain keratin filaments which symbolize differentiated keratinocytes of the 
outer stratum granulosum layer.1,3,4 The stratum granulosum is composed of 3-5 layers of 
cells and is characterized by the presence of lamellar bodies as well as keratohyalin granules. 
The two late differentiation markers filaggrin and loricrin are expressed and processed by 
these cell layers.6 The stratum corneum predominantly forms the primary skin barrier against 
cutaneous infiltration of chemicals, microbes and mechanical injuries.1,7 In the stratum 
corneum cells are held together by lipid bilayers, which form a rigid and insoluble structure 
known as cornified envelope. The stratum corneum is also involved in various active 
processes like regulation of water loss to outer environment from the skin, known as 
transepidermal water loss (TEWL).1,7     
 
The thickest part of the skin is the dermis containing sweat glands, sebaceous glands and hair 
follicles among other structures.8 The dermis also harbors a complex network of blood 
vessels and capillaries in addition to connective tissue. Thermoregulation of body is regulated 
by the dilation or contraction of these blood vessels.8 Collagen and elastin, which are present 





1.2 EPIDERMAL BARRIER AND IT’S DISRUPTION IN ATOPIC DISEASES 
The skin is metabolically active and several physiological phenomena help to maintain the 
skin barrier intact. Protection of the inner body from microorganisms in addition to physical, 
chemical, thermal and mechanical danger is the fundamental function of the skin (Fig.1).10 
Several factors are required to sustain the skin barrier function. These include prevention of 
excessive water loss, renewal of skin cells, cell to cell communication and interaction with 
the immune system. Upon epidermal barrier disruption, the initiatory reaction to cellular 
damage of the epidermal cells is a stimulatory alert to substitute the damaged cells and to 
maintain the homeostasis in the skin.11 Immune cells like epidermal Langerhans cells (LCs), 
dendritic cells (DCs) which are also known as skin-resident immune cells, are major players 
in homeostatic reestablishment.10 In response to skin injury, keratinocytes (KCs) produce 
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), Interleukin (IL)-1α, β, 
IL-6 and IL-18. These cytokines activate dermal DCs in the presence or absence of antigens. 
When KCs get activated due to stress signaling, they participate in further activation of 
dermal DCs by secreting interferon-α (IFN-α) (Fig. 1). Upon activation DCs boost skin-
resident CD4+ or CD8+ T cell proliferation (Fig. 1). Activated T cells amplify the 
inflammatory response in skin by producing chemokines and cytokines which in turn act on 
epithelial and mesenchymal cells such as KCs and fibroblasts (Fig. 1).10          
 
1.2.1 Skin irritants - physical and chemical  
The skin is susceptible to exposure by different irritants which can result in detrimental 
effects on barrier function and a subsequent damage of the epithelial cells.12 Several studies 
have been conducted to better understand the underlying mechanisms of acute and chronic 
irritation12. However, to study the pathogenesis of irritation at a cellular level in humans is 
difficult due to ethical reasons. Therefore mouse models were employed to study the physico-
chemical phenomena behind these reactions. Many studies have been reported using different 
chemical and physical irritants such as sodium dodecyl sulphate (SDS), croton oil, acetone, 
tape stripping.13 Perturbed skin barrier assessment is analyzed by measuring TEWL,  
electrical capacitance (stratum corenum hydration), percutaneous drug transport and skin 
color reflectance (erythema).13,14 A strong inflammatory response has been observed by 
Willis et al. (1993) on exposure of murine skin to 5% SDS for 48 hours (hrs).15 It has been 




the LCs.16 Tape stripping mediated barrier disruption is another common method used to 
study irritation, with less cytopathic effect on epithelial cells. Adhesive tape strip is 
commonly used to remove the layers of stratum corneum.17 Upon stratum corneum 




Figure 1: Skin barrier disruption results in inflammatory response.  
Mechanical injury and exposure to infectious agents or irritant results in skin barrier 
disruption and initiates inflammatory response. Keratinocytes upon barrier damage start 
producing pro-inflammatory cytokines such as IL-1β, IL-6, IL-18 and TNF-α which lead to 
activation of the dendritic cells followed by activation of mast cells and T cells. (reprinted 
from Skin immune sentinels in health and disease. Frank O. Nestle, Paola Di Meglio, Jian-
Zhong Qin and Brian J. Nickoloff, Nat Rev Immunol. Oct 2009; 9(10): 679–691, copyright 
2009, with permission from Springer nature). 
 
In alignment with the murine findings, similar pro-inflammatory immune responses was 






1.2.2 Atopic dermatitis (AD)    
 
 
AD is a heterogeneous chronic-relapsing skin disease. It is characterized by the presence of 
erythema, eczema, edema, excoriation, xeriosis, pruritus and a typical localization pattern21. 
Generally, commencement of AD starts during childhood.21,22 Epidemiological studies 
worldwide indicate an increase in the frequency of AD development in the last decades 
affecting nearly 10-20% and 1-3% of the children and adult populations, respectively.22-24 
 
Genetic and environmental factors play an important role in the development of AD but the 
underlying molecular mechanisms of AD are still not clear.25,26 The contribution of immune 
dysregulation and genetic factors as a consequence of which AD development occurs are still 
not clearly defined.22,26,27 Major events and different cells types involved in the development 
of AD are shown in figure 2.28 Genetically, a null mutation in the filaggrin gene encoding for 
the important barrier protein filaggrin, reported to be present in 20% of AD patients.24,25,29 
Skin barrier is formed of filaggrin and several other proteins which may also play important 
role in the AD development.  Furthermore AD development can be surpassed even though in 
the presence of filaggrin mutations indicating disruption of the skin barrier not sufficient for 
the disease development.30,31 Other T-cell types like T-reg, Th17, Th9 and Th22 have been 
reported to play a roles in AD pathogenesis but their explicit role in the progression of AD is 
not well defined (Fig. 2).32,33   
 
Keratinocytes are key components during the initiation of the disease by activating DCs 
leading to Th2 polarization, through secretion of high amounts of TSLP in atopic skin (Fig. 
2).21 Although T cells were previously considered to be critical for pathogenesis of AD and 
are redundant under particular conditions. These T cells can be substituted by innate immune 
cells including mast cells (MCs), eosinophils and macrophages.34-36 Thus, based on 
heterogeneity of cells and signaling cascades involved in AD which ultimately converge on 
barrier disruption, it is conceivable that perturbations in skin cells and immune deviations can 







                                       
Figure 2: Immune mechanism in the pathogenesis of AD.  
In patients with AD, a disturbed epidermal barrier leads to increased permeation of antigens, 
which encounter Langerhans cells (LCs), inflammatory dendritic epidermal cells (iDECs), 
and dermal dendritic cells (dDCs), activating TH2 T-cells to produce IL-4 and IL-13. DCs 
then travel to lymph nodes, where they activate effector T-cells and induce IgE class-
switching. IL-4 and IL-13 stimulate KCs to produce TSLP. TSLP activates OX40 ligand–
expressing dDCs to induce inflammatory TH2 T-cells. Cytokines and chemokines, such as IL-
4, IL-5, IL-13, eotaxins, CCL17, CCL18, and CCL22, produced by TH2 T-cells and DCs 
stimulate skin infiltration by DCs, mast cells, and eosinophils (EOS). TH2 and TH22 T-cells 
predominate in patients with AD, but TH1 and TH17 T-cells also contribute to its 
pathogenesis. The TH2 and TH22 cytokines (IL-4/IL-13 and IL-22, respectively) were shown 
to inhibit terminal differentiation and contribute to the barrier defect in patients with AD. 
Thus both the barrier defects and immune activation alter the threshold and self-reactivity in 
patients with AD (reprinted from Journal of Allergy and Clinical Immunology, Vol 131, Issue 
2, JK Gittler, JG Krueger, and E Guttman-Yassky, 300–313, copyright 2013 with permission 






1.3 KERATINOCYTES  
KCs are epithelial cells which conserve the physical and biochemical integrity of skin.38,39 
During differentiation to form skin barrier, KCs undergo complex morphological and 
cytostructural changes with the expression of different differentiation-dependent structural 
proteins such as involucrin, filaggrin, claudin etc. in the spinous and granular layers.38 KCs 
play crucial role in the cellular communication, pathogenesis of diseases and in maintaining 
the immune response.31,40,41 Deviation from skin homeostasis or barrier disruption act as 
activation signal for KCs in response to which they start producing different pro-
inflammatory cytokines such as TNF-α, IL-1α, TSLP to facilitate inflammation.10     
       
1.3.1 Role of keratinocytes in skin irritation  
As pointed out above, for maintaining skin homeostasis KCs are the crucial cells. By 
undergoing differentiation, they form rigid structure and consecutively enter into cell cycle 
arrest phase.42 IL-1α produced by KCs acts as primary alarm signal upon skin irritation or 
other skin disruption in the inflammatory pathway.43 Numerous, studies have demonstrated 
the ability of different irritants to induce IL-1α production in KCs, which further boost the 
production of other pro-inflammatory cytokines such as IL-1β, IL-6, IL,18, TNF-α by dermal 
and epidermal cells.42,44-47 Physical or chemical skin irritation leads to activation of proteases 
which cleave the pro-IL-1β into biologically active IL-1β which along with IL-1α support the 
activation of DCs and T cells.48  
  
1.3.2 Role of keratinocytes in AD 
Barrier deficiency in AD development and progression is primarily caused by KCs.49 KCs 
produce peculiar set of cytokines and chemokine’s such as high levels of chemokine ligand 
(CCL)5 (RANTES), thymic stromal lymphopoietin (TSLP) upon stimulation with IL-1and 
TNF-α to promote AD environment.20,50 It has been reported that KCs derived from AD 
patients produce high amount of granulocytes-macrophage colony-stimulation factor (GMC-
SF) in addition to TNF-α.51  Recent studies, demonstrating the involvement of KCs derived 
cytokines such as TSLP on the inflammatory response provide a deeper insight for the role of 
KCs not only in barrier formation, but also as collaborative cells along with DCs activation to 




results in production of chemokines such as CCL17, macrophage derived CCL22, which 
further foster infiltration of Th2 cells in the lesional AD skin.28 It has been shown that upon 
activation KCs produce IL-25 and IL-33 which act on mast cells (MCs), DCs and LCs.31,34      
 
1.4 MAST CELLS  
MCs are bone marrow derived cells which migrate to tissue through blood for maturation 
under the influence of stem cell factor (SCF). They can be identified by staining for tryptase. 
Skin MCs are belong to the connective tissue type and contain both chymase and tryptase 
(MCTC) while the mucosal MCs contains only tryptase and no chymase (MCT).
53-55 MCs are 
deemed to be among the first cells to respond to an allergen/injury and are considered as the 
instigating players in the IgE-mediated immediate type hypersensitivity. MCs degranulation 
can be mediated by human G protein coupled receptor MAS Related GPR Family Member 
X2 (MRGPRx2) activation by certain drugs, substance P or compound 48/80 (C48/80) in 
addition to classical FcεRI crosslinking by polyvalent allergen/agent through binding to IgE 
present on FcεRI.56, 57,58    
 
1.4.1 Role of mast cells in AD 
Profound degranulation of MCs along with their recruitment is observed in the lesions of AD 
skin.54,59 MCs degranulation has been shown to correlate with the severity of AD.60 MCs can 
regulate the recruitment as well as functions of cells participating in the skin inflammation 
through the production of cytokines, chemokines and growth factors (Fig. 3).61 For instance, 
by virtue of IL-4, IL-13 and TNF-α they induce cell adhesion molecule on endothelium, 
which can contribute in the recruitment of leukocytes.62-64 They can also control the 
differentiation of naïve T cells to Th1 or Th2 subtypes and increase the activation of T 
cells.65,66 MCs can also modulate primary B cell development and induce IgE synthesis in B 
cells.66-68 
 
MCs can interact with KCs, DCs and LCs by their mediators. By secreting tryptase 
(endogenous PAR-2 agonist) and histamine, MCs can stimulate KCs to express pro-
inflammatory chemokines and cytokines, growth factors and adhesion proteins.69,70 They 
can induce integrin on the LCs by TNF-α and promote their migration to lymph 




cytokines.74 Additionally, MCs can act like professional antigen-presenting cell by directly 




Figure 3. Skin mast cells sense and react to various danger signals.  
TLR, toll-like receptor; ET, endothelin; CRH, corticotropin releasing hormone; LN, lymph 
node (reprinted from Metz et al. 2007, Immunobiology 213 (2008) 251–260, copyright 2007 
Elsevier GmbH., with permission from Elsevier) 
 
1.5 PROTEASE ACTIVATED RECEPTOR (PAR)-2 
The KCs sense the extracellular proteolytic activity by a unique class of G-protein-coupled 
receptors (GPCRs), called PARs. Four PAR receptors have been reported with special 
cellular functions. Proteolytic cleavage of N-terminal end results in activations of PARs. 
Thus, a tethered ligand sequence (TLS) is exposed that binds to the second extracellular loop 
of the same receptor and sequentially causes receptor activation, signaling as well as receptor 
internalization. Contrary to other ligand binding GPCRs, such as activation and 
internalization of PARs leads to endosomal trafficking, ubiquitination and degradation of the 
receptors in lysosomes. Thereby, reconstitution of the cells surface with PARs relies on the 
de novo synthesis or transport of stored receptors within intracellular vesicles.80-83 Several 




allergic responses.84-88 PAR-2 activation is mediated by a broad range of endogenous 
proteases including serine proteases (e.g. KLK5, KLK14, tryptase) and exogenous proteases 
such as house dust mite (HDM) antigen Der p1.89-92 PAR-2 activation has been shown to 
induce itch, either directly upon activation of receptor on sensory nerve fibers in the skin, or 
indirectly by activating KCs or other immune cells (e.g. MCs), and consequently elicit a 
cascade resulting in release of pruritogens which in turn activate the sensory nerve fibers 
innervating the skin.93-96        
1.5.1  Role of PAR-2 in AD 
Severe skin barrier disruption leads to excessive dehydration, chronic skin inflammation, itch 
and enhanced risk of skin infections. Patients with AD, netherton syndrome (NS) or 
ichthyosis, suffer from extensive itch and ultimately develop erythematous scaly skin as a 
result of faulty skin barrier.36,97,98  
Along with kallikreins (KLKs) and endogenous protease inhibitors, PAR-2 as well as its 
activating proteases are important regulators of KC differentiation and skin barrier 
homeostasis. Interestingly, hyperkeratosis in different inflammatory skin diseases (e.g. AD or 
NS) is coincided by enhanced expression of PAR-2 and PAR-2 activating proteases.36,97,99  
 
1.6 THYMIC STROMAL LYMPHOPOIETIN (TSLP) 
TSLP is an IL-7 like cytokine and has been first identified in the mouse thymic stromal cell 
culture supernatants. TSLP promote the differentiation and growth of B cells in addition to 
proliferation of T cells.100,101 Several studies have reported that high affinity binding of TSLP 
needs concomitant binding to the TSLP receptor (TSLPR) and α-chain of IL-7 receptor.102,103 
Primarily TSLP is expressed by epithelia cells of skin, gut, thymus and tonsils along with 
stromal cells.104-106 TSLP leads to differentiation of Treg cells by instructing the thymic 
DCs.107 Intriguingly, human TSLP does not exert the same effects as the murine TSLP, 
despite that it activate immature CD11c+ myeloid DCs.106,108 Thereby, human DCs can 
induce naïve CD4+ T cell proliferation and triggers the production of IL-4, IL-5, IL-13 as 
well as TNF-α (fig. 7). On the other hand, TSLP activated DCs inhibits the production of 
anti-inflammatory cytokines IL-10 and IFN-γ.108 As a broad range of cells are influenced by 
TSLP, it has been implied to play a major role in numerous ailments like cancer, infections 
and inflammatory bowel diseases.109-111 However, TSLP being primarily an epithelial 
cytokines, has been expected to play a vital role in allergic diseases such as asthma and 




allergic asthma as well as AD and found responsible for defective airway inflammation and 
skin inflammation.113-115             
 
1.6.1 Role of TSLP in AD 
Skin barrier integrity is compromised upon acute injury or perturbation to the stratum 
corneum leading to induction of positive and negative alarm signals resulting in triggering of 
both homeostatic and inflammatory reactions in the skin.18,116 The damaged skin barrier 
further fuels the production of particular cytokines to promote skin inflammation.99,117,118 
TSLP is one of the cytokine, produced by KCs on skin barrier damage or stimulation with 
inflammatory cytokines (fig. 4).52 Although, the importance of TSLP in allergic 
inflammations is firmly established, the mechanisms behind the induction of TSLP 
production are not well known.35,119,120 Primary human KCs and skin explants have been 
shown to produce enhanced TSLP in response to viral, bacterial or inflammatory stimuli or 
upon physical/chemical perturbation to skin barrier.20,121,122 The role of TSLP in the 
manifestation of AD was not clear until it was reported that TSLP overexpression in the 
murine skin results in development of spontaneous dermatitis, the hallmark of human 
AD.34,106 Since epithelial cells are the primary source of TSLP, this further indicate KCs are 
the trigger factor in the AD development (Fig. 4).123  Subsequently, several studies verified 
TSLP as a primary initiator of AD.35,36,124 Development of AD like skin lesions have been 
observed upon direct administration of TSLP in skin. TSLP promotes the proliferation and 
differentiation of Th2 cells and consequently expression of TNF-α, IL-4, IL-5 and IL-13.106  
Furthermore, it was observed that expression of TSLP in KCs from AD patients is highly 
increased. Likewise, TSLP is associated with migration and activation of dermal DCs.125  
Thus, TSLP was considered as one of the key factors in triggering AD development. Mice 
overexpressing KCs specific TSLP, but lacking T cells developed skin inflammation, 
suggesting that for the disease progression T cells are not obligatory.34 In agreement with the 
previous study, other studies by using different AD models demonstrated that TSLP is 





                                        
Figure 4: Induction of TSLP production by keratinocytes.  
Disruption of skin barrier, allergen or cytokines derived from Th2 immune response triggers 
the production of TSLP by epithelial cells. Further, TSLP mediated activated DCs promote 
recruitment of T cells which further amplifies the production of pro-inflammatory cytokines 
and chemokines such as TNF-α, IL-4, IL-5. Mast cells also start producing other cytokines 
like IL-5, IL-13, upon activation by TSLP (reprinted from Hamida Hammad et al. 2008: DCs 
and epithelial cells: linking innate and adaptive immunity in asthma: Nature Reviews 
Immunology 8, 193-204 (March 2008), Copyright © 2008, with permission from Nature 










1.7 OBJECTIVES  
Over the years, TSLP has been well established as critical pro-inflammatory cytokines with 
implications in inflammatory disorders. TSLP promotes pro-allergic Th2-type inflammatory 
responses through activating leukocytes. However, the mechanisms of TSLP regulation in 
skin irritation, contribution of endogenous MCs mediators in TSLP production and its role in 
AD development is not clear. In this thesis, mechanisms underlying the TSLP production by 
skin irritation, MC mediators and its contribution in the AD development was investigated. In 
this thesis the following questions were tackled.  
1. Are the TSLPR-/- mice protected from AD development under the TNF deficiency? 
2. Is skin barrier disruption responsible for elicited TSLP production and what are the 
signaling cascades involved? Do the responsible pathways operate cooperatively or 
independently and at what levels?  
3. Are the mast cells plays a role in TSLP production by the keratinocytes? And if so 
what are the mediators and mechanisms behind MCs and KCs cross-talk in the 
production of TSLP?      
Answer to these questions will help in better understanding of the mechanisms underlying 
inflammatory processes  in the AD development and may help in designing more irresolute 
clinical management by exclusive aiming of pathways involved individually or collectively 
depending on the situation. 
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2  MATERIALS AND METHODS 
2.1 MATERIALS 
Detailed list of used reagents, antibodies, solutions, labwares and softwere are given below: 
Details about antibodies, instruments, chemicals, buffers, solutions, reagents, labwares and 
software used are listed below: 
Table 1. List of reagents  
 
 Reagents Supplier Catalog Number 
Agarose Biozym 840004 
Albumin from chicken 
egg white, Grade V 
Sigma-Aldrich A5503-10G 
Antibody diluent (Dako 
REALTM) 
DAKO Diagnostika S0809 






Beta mercapto ethanol Sigma-Aldrich M6250 






Compound 48/80  Sigma-Aldrich C2313 





Desloratadin  Sigma-Aldrich D1069 
Dispase BD Biosciences 354235 
Desoxyribonucleic acid 
(DNA) Molecuar Weight 
Roche 11721925001 
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XIII – 50 base pair (bp) 
ladder  
DNA Molecular Weight 
XIV – 100 bp ladder  
Roche 11721933001 
Dulbecco´s phosphate-
buffered saline (PBS) 
GE Healthcare  H15-002 




Fetal Bovine Serum 
(FBS) 
PAA NC9862466  
High sensitivity ChIP kit Abcam Ab185913 
Histamine Sigma-Alrich H7125 
Human TSLP Duo Set R&D Systems® DY1398 
Isoflurane (Forane)  Abott  
IMDM medium PAA E-15-819 
JNJ 10191584 maleate Sigma-Aldrich J3830 
LightCycler® FastStart 
DNA Master SYBR 
Green I 
Roche   12239264001 
Mouse mast cell 
protease(mMCP)-6  
R&D Systems® 3736-SE 
Mouse TSLP Duo Set R&D Systems® DY555 
Nucleo Spin® RNA II Macherey-Nagel, 
Düren 
740955.250 
Penicillin/Streptomycin Biochrom A 2212 
Phorbol-12-myristate- Sigma-Aldrich P8139 




Proteinase K  Macherey-Nagel 740506 
Reverse Transcription 
Kit 
Applied Biosystems 4368814 
SLIGRL-NH2 Tocris  1468 




peroxidase (HRP)  
R&D Systems® DY998 
Sulfuric acid, H2SO4 Merck 1090734000 
TAE buffer (50x) Genaxxon M3087.1000 
Trypsin / EDTA 
Solution 
Gibco® BD R-001-100 
Tryptase Sigma-Aldrich 650366-M 
Trypsin inhibitor from 
Glycine max (soybean) 
Sigma-Aldrich T9003 
Tween 20 Sigma-Aldrich P1379-500ML 





Table 2. List of antibodies 
Antibody Supplier Catalog Number 
  Anti-mouse mouse mast 
cell protease-    





  Anti- mouse IL-1 alpha Abcam ab7632 
  Anti-human tryptase R&D Systems® 
 
AF2370 
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  Anti-NF-κB  Abcam Ab19870 
  Anti-PAR-2 (SAM11) Santa Cruz 
Biotechnology, Inc. 
sc-13504 
  Mouse IgG2a R&D Systems® MAB003 
  Normal goat IgG control R&D Systems® AB-108-C 
 
Table 3. List of materials 
Material Supplier Catalog 
Number 
Biosphere® Filter Tips 
    0.5-20 µL 
    2-100 µL 





Cell strainer, 40 µm BD FalconTM 352340 
Cell strainer ,100 µm BD FalconTM 352360 
Culture flask 
   T 75 
   T 175 
Cellstar®, Greiner-Bio  
658175 
660175 
Conical tube ,15 mL BD FalconTM 352096 
Conical tube ,50 mL BD FalconTM 352070 
Descosept AF Dr Schumacher GmbH sc 311001 
LightCycler® Capillaries Roche 0492929200
1 
Micro tube, 0.5 mL Sarstedt 72.699 
Micro tube, 1.5 mL Sarstedt 72.690.001 
Micro tube, 2 mL Sarstedt 72.691 




Quality Tips without filter 
    10 µL 
    200 µL 






    5 mL 
    10 mL 
    25 mL 




96-well cell culture plate Cellstar®, Greiner-Bio 655185 
Petri dish Greiner-Bio 632181 
 
Table 4. List of instruments 
Instrument Model Supplier 
Cell counter CASY® - TTC-2FC-1142 Innovatis AG, 
Reutlingen 










Electrophoresis System Sub-Cell® GT Bio Rad, 
München 
Gel Imager Gene Genius Syngene, 
Cambridge 
 Inverted Reflected-Light 
Microscope 
Zeiss Axiovert 10 Zeiss, Jena 
Light Cycler  Roche, 
Penzberg 
Microplate reader Dynatech MRX Dynex 
Technologies
, Chantilly 
Multipipette  Multipipette® plus Eppendorf, 
Hamburg 




Pipettor Pipetus standard Hirschmann 
Laborgeräte, 
Eberstadt 
PCR machine Px2 Thermal Cycler Thermo 
Electron 
Corporation 
Power Supply POWER PAC 300 BioRad, 
‚München 
Spectrophotometer Nano Drop 1000 Thermo 
Scientific, 
Schwerte 
Tabletop centrifuge with 
refrigeration 
Centrifuge 5417C Eppendorf, 
Hamburg 
Tabletop Centrifuge Centrifuge 5417R Eppendorf, 
Hamburg 
Thermomixer Thermomixer comfort Eppendorf, 
Hamburg 





Waterbath MA6 Lauda, 
Lauda-
Königshofen 
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2.2 METHODS  
2.2.1 Animal experiments 
All experimental procedures were approved by the local State office of Health and Social 
Affairs and performed in agreement with their protocols. Mice were either purchased from 
Jackson, Charles River or generated and breed at animal facility of Forschungseinrichtungen 
für Experimentelle Medizin (FEM). 
 
2.3  MOUSE MODELS 
2.3.1  In vivo AD model 
 
Figure 5. Experimental design for the in vivo inducible AD model   
 
AD was induced with an adapted protocol from Dahten et al. 2008.127 Concisely, 10 weels old 
female C57BL/6 mice with wt, TNF-/-, TSLPR-/- and TNF-/-TSLPR-/- double knockout 
mice were sensitized using  three consequent intraperitoneal injections (i.p) with 100 µl of 10 
µg ovalbumin (OVA) adsorbed to 1.5 mg Al(OH)3 (alum) on days 1, 14 and 21 (black arrow 
on figure 1 ). The belly of mice was wet shaved on day 21. Followed by tape stripping and 
epicutaneous application of 100 µg OVA allergen through utilizing patch test method for a 
period of one week. Three allergen exposures, each of one week duration was given to each 
mice at the same site on the skin with a two week periods interruption in between without any 
allergen. On day 71, mice were anesthetized by using isoflurane followed by sacrifcation by 
cervical dislocation. Blood was collected and 5 mm2 biopsies were taken for further analysis 
by ELISA and immunohistochemistry respectively. Photographs of the path area were taken 
for assessment of severity score. Skin biopsies from the patched skin area were embedded in 
O.C.T. compound or in formalin for further processing by immunohistochemistry. Rest of the 
skin was frozen for mRNA isolation and whole skin lysate preparation. All frozen samples 
were stored at -80 °C unless used for further analysis.                 











Figure 6. Experimental scheme of skin irritation model with different treatments ex vivo. 
10 week old female C57BL/6 (wt) mice were anesthetized and sacrified, wet shaved at belly 
region and exposed 30 times tape stripping using cello tape or left non-irritated. 5 mm2 punch 
biopsies were taken. Tape stripped skin biopsies were incubated in hydrocortisone 
hemisuccinate‐free medium with recombinant interleukin-1-receptor antagonist (IL‐1Ra) at 
200 ng/ml and/or anti-PAR-2 antibody (or mIgG2a control) at 5 µg/ml. Skin explants without 
tape stripping were exogenously stimulated with recombinant mouse interleukin (IL)-1α  (100 
ng/ml)and/or PAR-2-Ag (2-Furoyl-LIGRLO-amide, 500 nmol/L). After 12 hrs of incubation, 
culture supernatant were collected and used for ELISA.  
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In vivo skin irritation 
The experimental procedure is depicted in figure 7. After scarification, mouse skin was 
chopped and homogenized by pre-chilled precellys homogenization (PEQLAB, Erlangen, 
Germany) in lysis buffer (2 mmol/L EDTA, 1 mmol/L dithiothreitol, 25 mmol/L Tris [pH 
7.8], 1% Triton X-100 and 10% glycerol) with protease inhibitor cocktail (Roche, Basel, 
Switzerland) and used for ELISA. Protein was quantified by bis-cinchinonic acid (BCA) 
assay (Pierce Laboratories, Rockford, USA). 







Figure 8. Scheme showing mast cell degranulation model ex vivo. 
Mice were anesthetized and sacrified and gently wet shaved at belly region. 5 mm2 punch 
biopsies were taken and incubated in hydrocortisone hemisuccinate‐free medium either with 
different doses of tryptase or histamine or mast cell supernatant (1%) or mMCP6 (10 ng/ml) 
or with C48/80 (100µg/ml) for stimulation. For the inhibition skin explants were exposed to 
mast cell supernatant for 30 minutes prior to treatment with anti-mMCP6 (5 µg/ml) or anti-
PAR-2 (5 µg/ml) antibodies. As a control, skin biopsies were either left untreated or treated 
with respective isotype control antibody (goat-IgG or mouse-IgG). Culture supernatant were 
collected and TSLP was measured by ELISA after 12 hr of incubation.     
 











supernatant   
Wet shaving  Sacrification  
 
Culturing of  
skin biopsies 
        
            +/- 




















MATERIALS AND METHODS 
33 
 
Figure 9. Scheme depicting mast cell degranulation model with different treatments in 
vivo. 
The experimental procedure is depicted in figure 9. After scarification, mouse skin was 
chopped and homogenized by pre-chilled precellys homogenization (PEQLAB, Erlangen, 
Germany) in lysis buffer (2 mmol/L EDTA, 1 mmol/L dithiothreitol, 25 mmol/L Tris [pH 
7.8], 1% Triton X-100 and 10% glycerol) with protease inhibitor cocktail (Roche, Basel, 
Switzerland) and used for ELISA. Protein was quantified by bis-cinchinonic acid (BCA) 
assay (Pierce Laboratories, Rockford, USA). 
2.4 CELL CULTURE METHODS 
2.4.1 Isolation, culturing and treatment of human primary keratinocytes  
Human KCs were isolated from foreskin and processed as described previously. The fore skin 
was obtained after circumcisions, with informed consent of the patients and approval by the 
university Ethics committee. All the experiments were conducted according to the Declaration 
of Helsinki Principles. After the 2nd passage, 7.5x103 cells/well were seeded in a 96-well 
plate in KC medium and grown to 70-80% confluence. For Luciferase assay 40-50% 
confluent cells were used. After reaching confluence, the medium was changed to 
hydrocortisone hemisuccinate free KC medium for 24 hr, and cells were stimulated with 
various concentrations of IL-1(2,5,10,20 ng/ml), nafamostat 5 µg/ml, rhIL-1Ra 200 ng/ml, 
SLIGRL 100 µM/ml and 0.1% MC lysate 24 hr. Supernatants were collected and measured by 
a human TSLP ELISA Kit (R&D Systems). 
2.4.2 Enzyme linked immunosorbent assay (ELISA) 
 
Figure 10. Scheme of sandwich based - enzyme linked immunosorbent assay (ELISA) 
(adapted from Epitomics - an Abcam Company).  
 
ELISA is an enzyme immunoassay used to measure the unknown level of antigens in serum 
or supernatant. In this study we have used sandwich based ELISA to quantify the level of 
protein. Here, first the primary antibodies were coated on the surface of the plate and the 
MATERIALS AND METHODS 
34 
 
target protein from serum or supernatant were incubated for specific binding. The detection 
antibodies were incubated over the surface of bound specific antigen. In the next step, the 
plates were incubated with Horseradish peroxidase (HRP) linked biotinylated antibodies, 
which can convert a chromogenic substrate. The enzymatic reaction leads to the color change 
which was measured by spectrophotometer. The concentration of protein in the samples was 
calculated by the means of standard curve. All the steps were performed at room temperature 
and in dark from HRP-linked antibody. 
2.4.2.1  Mouse and human TSLP ELISA 
In vitro, ex vivo, or in vivo experiments were performed and cell free supernatant or serum 
from mice and human epidermal sheet were obtained and measured for mouse and human 
TSLP levels. Analysis was performed based on TSLP ELISA kit from R&D system (mouse) 
and ebiosciences (human) according to manufacturer’s instructions. 
2.4.3 RNA isolation  
Frozen skin samples from mice were homogenized by pre-chilled precellys homogenisation 
(PEQLAB, Germany) beads tube in 500 μl RA1 lysis buffer (NucleoSpin® RNA isolation kit) 
with 5 μl β-mercaptoethanol (β-Me) at 5500 rpm for 2 times for 30 sec with 5 sec pause. 
Homogenized samples were transferred to NucleoSpin filter and centrifuged at 11,000 g for 2 
min at room temperature. Supernatant was transferred to sterile eppendorf tubes carefully 
without disturbing the pellet and 500 μl of RNase-free water was added with 10% proteinase 
K and mixed well for tissue digestion. The lysate was incubated for 15 min at 55 °C. After 15 
min, lysate was centrifuged at 10,000 g for 3 min. For RNA isolation from the keratinocytes 
lysis was performed by using 300 µl RA1 buffer with 3 µl β-mercaptoethanol (β-Me).    
Further, RNA isolation was performed according to manufacturer’s instruction along with 
DNase digestion step for 15 min at room temperature. RNA was eluted with 60 μl of RNase-
free water. Using NanoDrop UV-Vis spectrophotometer, RNA concentration was measured at 
260 nm. Later, quality of RNA was checked by 2% agarose gel. The eluted samples were 
stored at -80 °C for further analysis. 
2.4.4 Reverse transcription  
Reverse transcription of total RNA into single stranded cDNA was performed with TaqMan® 
reverse transcription reagent according to manufacturer’s instruction. The kit contains a 
recombinant Moloney Murine Leukemia Virus Reverse Transcriptase, random hexamers and 
oligo d(T). 1 μg of total RNA was used for reverse transcribtion in to cDNA in thermo cycler 
with following steps as given in table 5. 
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Table 5. cDNA synthesis program 
Process Temperature (°C) Time (min) 
Incubation 25 10 
Reverse transcription (RT) 48 40 
RT inactivation 95 5 
 
All cDNA samples were stored at -20 °C. 
2.4.5 Real-time polymerase chain reaction  
Fluorescence based real time quantitative polymerase chain reaction (qPCR) was performed 
on the cDNA for the quantification of gene expression in skin samples or keratinocytes. qPCR 
was performed with LightCycler® FastStart DNA Master SYBR Green I (Roche) according 
to the experimental protocol shown in table 6. The cDNA was pre-diluted 1:3 and the primers 
used were designed by Primer3 software and are given in table 7. The formation of PCR 
product is measured by increased level of fluorescence caused by specific binding of SYBR 
green fluorescence dye to double-stranded DNA (SYBR green- Double-Stranded DNA 
(dsDNA)). To ignore the non-specific binding by SYBR green, PCR buffer also contains a 
reference dye to normalize the specific binding. The cycle number of crossing point (CP) or 
the threshold cycle value (CT) is the number of cycle at which significant increase of the 
normalized florescence is first measured. Depending on CT values of a gene and the 
efficiency of primers, the relative expression of a gene was calculated. The expression level of 
target gene was normalized to the expression level of housekeeping gene i.e hypoxanthine-
guanine phosphoribosyltransferase (HPRT) using the 2-ΔΔCT method. 







25mM MgCl2 0.80 3-5 mM 
10μM Forward Primer 0.25 100-500 nM 
10μM Forward Primer 0.25 100-500 nM 
RNase-free H2O (makeup the 
volume up to 
 




cDNA 2  
Table 7. Primer sequences used for real time polymerase chain reaction 


































2.4.6 Immunoprecipitation assay (IP):  
For immunoprecipitation of tryptase, the cells were lysed in PBS containing protease 
inhibitors using freez-thaw cycles. The lysates were diluted twenty-fold with PBS and 
incubated with protein G beads (Santa Cruz Biotechnology) and human anti-tryptase 
polyclonal antibody (R&D systems) or goat IgG isotype control. Immunoprecipitated mast 
cells (MCs) lysate was collected, re-suspended in sample buffer and analyzed by 
immunoblotting.  
2.4.7 Immunoblotting:  
The MC lysates, immunoprecipitated with human anti-tryptase antibody or goat IgG isotype 
control, were suspended in sample buffer, loaded onto 10% polyacrylamide gels, and 
transferred to polyvinylidene difluoride membranes. The membranes were probed with anti-
tryptase antibody, detected using appropriate secondary antibody conjugated with horseradish 
peroxidase (Santa Cruz Biotechnology), and enhanced with a chemiluminescent kit (Pierce).  
MATERIALS AND METHODS 
37 
 
2.4.8 Chromatin Immunoprecipitation (ChIP) assay: 
Keratinocytes (1.2 x105 cells/condition) were stimulated for 30 minutes using IL-1 and/or 
PAR-2 agonist. Chromatin was prepared using Chromatrap Enzymatic Shearing Kit 
(Chromatrap) as per manufacturer instructions and the chromatin resolved on a 1% agarose 
gel for size confirmation and shearing quality. The chromatin was further processed using 
Abcam high sensitivity ChIP kit (Abcam). Immunoprecipitation was carried out using anti-
NF-ĸB antibody, and rabbit IgG as control. After column purification DNA was analysed 
using SYBR Green PCR kit and the rotor gene thermocycler (both from Qiagen). ChIP DNA 
was normalised to that of input DNA. For the human IL-8 promoter region EpiTect ChIP 
qPCR primers were purchased from Qiagen. The sequences of primers and conditions are as 
specified in table 8. 
 
 
Figure 11. Graphical depiction of ChIP assay. Protein and associated chromatin in living 
cells are crosslinked using formaldehyde. The crosslinked DNA–protein complexes 
(chromatin-protein) are then sheared into ∼500 bp DNA fragments using either enzymatic 
digestion or physical shearing by sonication. The DNA-protein complexes are then 
immunoprecipitated by an appropriate protein-specific antibody. After the cross-links are 
reversed, the associated DNA fragments are eluted, which is followed by 
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immunoprecipitation of the crosslinked complexes and analysis of the resultant DNA by 
qPCR. (adapted from Sigma-Aldrich) 
Table 8. Sequences of primers used for chromatin immunoprecipitation 
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2.4.9 Plasmid Construction, transfection and luciferase assay: 
 
 
Figure 12. Graphical summary of cloning by restriction enzymes. (reprinted from 
ThermoFischer Scientific)  
Human TSLP promoter fragment was amplified by PCR from genomic DNA isolated from 
human primary KCs, using Q5 high-fidelity DNA polymerase (New England Biolabs). Kpn1-
ended primers, and NheI-ended antisense primers were used to generate the 4.2kb human 
TSLP fragment. The fragment was cloned into the pGL4.15 basic vector (Promega) using 
restriction enzyme cloning and its sequence was verified by sequencing. 
Keratinocytes (1.2 x105 cells/condition) were transfected with 1.6µg of TSLP promoter 
luciferase reporter plasmid and 0.4µg of the Renilla luciferase reporter vector pRL-TK 
(Promega) using FuGENE 6 transfection reagent (Promega) according to the manufacturer’s 
protocol. After transfection, cells were cultured for 24 h, then stimulated for 24 h with 
interleukin (IL)-1α and/or PAR-2-Ag (SLIGRL). Cells were harvested and lysed in 100 µl of 
lysis buffer (Promega). The luciferase activity was measured by the dual-luciferase assay 
system kit (Promega) using a VictorTMX3 luminometer (PerkinElmer). All values were 
normalized to Renilla luciferase activity. 




2.5  STATISTICAL ANALYSIS  
Normally distributed data are depicted as mean ± SEM and non-normally distributed data are 
shown as median ± range. Experiments with only two groups were analyzed using t-test 
(paired or unpaired) or Wilcoxon matched paired test, when groups were not normally 
distributed; for more than 2 groups, depending on the data distribution, 1-way analysis of 
variance (ANOVA) was used, followed by Bonferroni multiple comparisons test or Kruskal-
Wallis test and Holm-Sidak multiples comparison test. Statistical analyses were performed 
with GraphPad Prism version 6 (GraphPad Software, USA). P value less than 0.05 was 




















3.1 TSLPR-/- MICE ARE PROTECTED FROM ENDOGENOUS TNF-
DEFICIENCY- MEDIATED AD DEVELOPMENT 
Numerous studies have established a role for TSLP as a Th2-promoting cytokine and master 
switch of atopic dermatitis (AD).41,128-130 As TNF-α is well established elicitor of TSLP131 the 
interaction between TNF and TSLP in the development of AD in mice was investigated. As 
suspected TNF-/- mice developed profound AD symptoms compared to Wt mice but 
interestingly TSLPR-/- mice as well as TNF-/-TSLPR-/- were protected from AD 
development. The three genotypes (Wt, TSLPR-/- and TNF-/-TSLPR-/-) showed significantly 
less symptoms of AD compared to TNF-/- mice (Fig. 13 a, b).  
Figure 13. Protection of AD in TSLPR-/- mice in the absence of TNF. (a) AD 
development is suppressed in TNF-/-TSLPR-/- double knockout mice (b) symptom score 
which represents a characteristic of dermatitis. Data was analyzed using one way ANOVA 
with Holm-Sidak multiple comparison test.  Mean ± SEM of n = 8-12 mice/group. (*p<0.05, 
**p<0.01). 
 
                        Wt                  TNF-/- 





These results show that TNF deficiency predisposes to AD in a TSLP dependent manner. In 
contrast, at the baseline the skin of TNF-/- mice was normal and healthy as Wt, TSLPR-/- and 
TNF-/-TSLPR-/- genotypes with comparable MC number, T cells, epidermal and dermal 
thickness (data not shown), indicating that the skin structure does not require TNF-α and/or 
TSLPR for development and maintenance.      
 
3.2  SKIN IRRITATION INDUCES TSLP PRODUCTION IN MURINE SKIN EX 
VIVO 
3.2.1 Skin irritation induces TSLP production in murine skin by IL-1 and PAR-2 
dependent pathways ex vivo  
Various studies have shown that skin barrier disruption either by genetic manipulations or 
physical/chemical irritation can induce robust TSLP expression20,36,122,123. Tape stripping, as a 
method for inducing physical irritation mediated barrier disruption and is also part of the AD 
model established in our group. To address the mechanisms behind physical irritation induced 
TSLP expression, we subjected the murine skin to tape stripping and studied the skin explant 
ex vivo (Fig. 6). As expected, tape stripping mediated barrier disruption induced TSLP 
production in a time dependent manner (Fig. 14a), consistently with the previous report20, but 
now providing kinetic resolution. 
As keratinocytes (KCs) express interleukin (IL)-1 and protease activated receptor (PAR)-
291,132,133 it was hypothesized that disruption of skin barrier triggers activation of IL-1 and 
PAR-2 pathways concurrently to trigger signaling pathways leading to TSLP induction. To 
test this, we neutralized the pathways individually as well as jointly by means of interleukin-1 
receptor antagonist (IL-1Ra) and a function-blocking anti-PAR-2 antibody (Fig. 14b). 
Neutralization of PAR-2 or IL-1 pathways alone blunted the TSLP production but blocking of 
both pathways concurrently resulted in amplified suppression compared to inhibition of either 
pathway individually (Fig. 14b).       
To verify the interaction between PAR-2 and IL-1 in the induction of TSLP, the next 
reciprocal approach was to activate the two pathways exogenously by providing respective 
stimuli. It was found, that TSLP production was upregulated upon stimulation with protease-
activated-receptor-2-agonist (PAR-2-Ag) as well as recombinant IL-1 (Fig. 14c). Yet, 
simultaneous activation of both pathways resulted in enhanced TSLP production compared to 




Figure 14. Skin irritation induces thymic stromal lymphopoietin (TSLP) expression via 
interleukin (IL-1) and protease-activated receptor (PAR)-2 ex vivo. (a) Kinetics of tape 
stripping induced TSLP production. TSLP was measured in culture supernatant by using 
enzyme-linked immunosorbent assay (ELISA) after different incubation times. (b) Murine 
skin explants after tape stripping, were incubated with anti-PAR-2 antibody (mIgG2a served 
as the isotype control) or interleukin-1 receptor antagonist (IL-1Ra) either alone or in 
combination. (c)  Naïve murine skin biopsies (i.e. without tape stripping) were incubated with 
mIL-1α alone or protease-activated receptor-2-agonist (PAR-2-Ag) or in combination. (b) and 
(c) TLSP was measured by ELISA after 12 h. The data, given as mean ± SEM from 12 






with Dunn’s multiple comparison test on the normalized data (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). 
3.2.2  IL-1 and PAR-2 pathways collaborate in physical irritation mediated TSLP 
production in vivo 
As a next step it was investigated whether the ex vivo findings are interchangeable to the 
intact skin in vivo. A tape stripping model was performed after the neutralization of IL-1, 
PAR-2 or both by using function-blocking antibodies. The experimental scheme is shown in 
figure 7. TSLP abundance in the skin was inhibited by intervention with PAR-2 or IL-1 
pathways, while simultaneous inhibition of both pathways resulted in a profound decrease of  
Figure 15. Skin irritation mediated TSLP production is driven by IL-1 and PAR-2 in 
vivo.  20 µg of anti-PAR-2 and/or anti-IL-1 (mIg2a and rIgG served as control) was 
intradermally injected in each mouse. (a) TSLP was measured in skin lysate using ELISA. (b) 
mRNA expression of TSLP in murine skin. Data are shown as mean ± SEM of 6 independent 
experiments and was analysed by Kruskal-Wallis test combined with Dunn’s multiple 






TSLP (Fig. 15a). The inhibition at mRNA expression level was similar and TSLP transcript 
levels dropped to more than 40% of control when IL-1 and PAR-2 pathways were 
concomitantly blocked (Fig. 15b). These results indicate that irritation mediated TSLP 
response results from concurrent activation of IL-1 and PAR-2 pathways.                                                                                                
3.2.3 PAR-2 agonist and IL-1 collectively induce TSLP in primary human 
keratinocytes 
To delineate the findings in murine system are intimated in humans, primary human KCs 
were stimulated with IL-1α (at different concentrations) and PAR-2 agonist alone as well in 
combinations, and TSLP levels were quantified. In this experimental setting, IL-1α induced 
TSLP in a dose-dependent manner while stimulation with PAR-2-Ag alone was without effect 
(Fig. 16a). Furthermore, TSLP induction was more prominent under co-stimulation with 
PAR-2-Ag and IL-1α and this was seen at all the tested concentrations of IL-1α. An actual 
synergistic effect was apparent at lower IL-1α concentrations (2 ng/ml), which by its own 
were unable to induce detectable TSLP response (Fig. 16a).  
 Two TSLP mRNA isoforms have been reported in humans. The short isoform is 
constitutively expressed and shown to exert ant-microbial properties whereas long isoform is 
conjugated to inflammation.134,135  To examine the influence of IL-1 and PAR-2 pathways 
activation on the TSLP isoforms, human KCs were stimulated as described above and 
harvested for RNA extraction after 2.5 h. Actually the long isoform was barely expressed 
before the stimulation, but was dose-dependently induced by IL-1α (Fig. 16b). The PAR-2 
agonist evidently collaborated with IL-1 in the upregulation of the long isoform (Fig. 16b). 
Contrary to the expression of long isoform, the short isoform was clearly detectable and not 
significantly modulated by IL-1, PAR-2 or the two jointly although there was a tendency of 
PAR-2-Ag to augment the transcript (Fig. 16c). Collectively, IL-1 and PAR-2 pathways 
concertedly trigger TSLP production also in human KCs by facilitating the expression of its 
long isoform.                                                             
3.2.4 PAR-2 and IL-1 pathways converge on the TSLP promoter by concerted 




The above findings indicated that the PAR-2 and IL-1 triggered signaling cascades may 
merge on the TSLP promoter. NF-ĸB is the major transcription factor in the transcriptional 
activation of TSLP gene.135 Four consensus binding sites (BS)s have been identified in TSLP 
promoter (designated BS1-BS4, see Fig. 17a), two of these BSs have been involved in TSLP 
induction (BS1 and BS4).131,136,137 
 
Figure 16. PAR-2 and IL-1 by working together preferentially induces the long TSLP 
isoform in human keratinocytes. (a) Human primary keratinocytes were stimulated with 
PAR-2-Ag and/or IL-1α for 24 h. TSLP protein levels were measured by ELISA in culture 
supernatants after stimulation. (b) Gene expression of the long and (c) short TSLP isoforms 
after incubation with PAR-2-Ag and/or IL-1α for 2.5 h was quantified by real time 
quantitative polymerase chain reaction (RT-qPCR). Results are expressed as mean ± SEM 
from 9 independent experiments and analysed by paired t-test (*p<0.05, **p<0.01, 
***p<0.001).  
 
To study NF-ĸB binding to these BSs under given experimental settings, nuclear extracts 
were prepared from IL-1α and/or PAR-2-Ag treated KCs and ChIP assays were performed. 







(Fig. 17b,c), but not at BS2 or BS3 (Fig. 18). Combined stimulation with IL-1α and PAR-2-
Ag resulted in concerted recruitment. Specially, NF-ĸB binding to BS4 was barely detectable 
upon IL-1 or PAR-2 activation alone yet became profound when the signaling cascades were 
















Figure 17. NF-ĸB binding to the TSLP promoter is promoted by IL-1 and PAR-2. (a) 
Diagrammatic representation of the consensus NF-ĸB binding sites in -3.8kb region of the  
human TSLP promoter. (b) Recruitment of NF-κB to BS1 and (c) Recruitment of NF-κB to 
BS4 of the human TSLP promoter upon stimulation with PAR-2-Agonist (PAR-2-Ag) and/or 
IL-1α. (d, e) Beta-actin and GAPDH promoter regions were used to verify that PAR-2-
Agonist (PAR-2-Ag) and/or IL-1α stimulations do not alter binding affinity of RNA 
polymerase II to meaningful regions of housekeeping genes. Results from one representative 



























To rule out non-specific effects of the according treatments, the 5’-upstream regions of beta-
actin and GAPDH were used as controls. As expected, RNA polymerase II binding to 
upstream regions of these genes was comparable across conditions in accordance with 
housekeeping-like character of the genes. In addition, the validity of the ChIP approach was 
confirmed by using an isotype control antibody comparing it directly with the specific 
antibody in different conditions (Fig. 18). To further validate the specificity of the ChIP 
antibody, the well-documented NF-ĸB-BS from the IL-8 promoter138 was used as a positive  
control for activation-dependent NF-ĸB binding (Appendix Fig. 29). 
Figure 18. IL-1 and protease activated receptor (PAR-2) activation leads to recruitment 
of NF-ĸB to binding sites (BS)s 1 and 4, but not BS2 and BS3 of the human TSLP 
promoter. Recruitment of NF-ĸB at BS1 (a), BS2 (b), BS3 (c), and BS4 (d) of the human 
TSLP promoter region, in comparison to IgG isotype control antibody. Promoter regions of 
(e) Beta-actin and (f) GAPDH upon stimulation with PAR-2-Ag and IL-1α (10 ng/ml) in 
comparison to IgG isotype control antibody. Results from one representative experiment of 3 









Taken together, the presented results suggest that PAR-2-and IL-1-mediated TSLP induction 
is triggered by their joint activity at the TSLP promoter through collaborated recruitment of 
NF-ĸB to its most biologically meaningful binding site.  
3.2.5 PAR-2 and IL-1 induce transcriptional activation of the TSLP promoter in 
human keratinocytes 
To investigate the role of IL-1 and PAR-2 in the activation of the TSLP promoter, was 
employed transient transfection of sub-confluent human primary KCs with a proximal 4.2 kb 
construct containing the transcriptional start of human TSLP promoter fused to a firefly 
luciferase gene. The response to IL-1 and/or PAR-2Ag was quantified by measuring 
luciferase activity. At baseline, little promoter activation was observed. PAR-2Ag or low 
concentration of IL-1 (2 ng/ml) alone showed no induction of TSLP promoter activity against 
control but the combination of both stimuli resulted in profound activation (Fig. 19), 
emphasizing the hypothesis that both pathways merge at the TSLP promoter. At a higher 
concentration IL-1 (20 ng/ml) was able to increase the TSLP promoter activity on its own, but 
the combined stimulation with PAR-2-Ag further enhanced the activity. Collectively, these 
results further support an important role of the PAR-2 signaling cascade in the co-activation 
of the TSLP promoter, particularly in the presence of low levels of IL-1. 
  Figure 19. IL-1 and PAR-2 mediated transcriptional activation of the human TSLP 




plasmid containing the human TSLP promoter and 0.4 µg of the Renilla luciferase reporter 
vector pRL-TK. After 24 h of transfection, KCs were stimulated  with IL-1 and/or PAR-2-Ag 
for 24 h. Whole-cell lysate was prepared and luciferase activity was measured. Renilla 
luciferase activity was used for normalization. Data are given as mean ± SEM from 9 
independent experiments and was analyzed by Kruskal-Wallis test combined with Dunn’s 
multiple comparisons test (**p<0.01, ****p<0.0001). 
 
Figure 20. Graphical depiction of the mechanism of skin irritation mediated TSLP 
induction. (a) PAR-2 pathway activation leads to a moderate enhancement in NF-ĸB activity, 
(b) while IL-1 pathway activation alone has a more intense effect on this signaling route in 
comparison to PAR-2. (c) Yet, upon combined activation of the IL-1 and PAR-2 pathways, by 
physical skin irritation, leads to an amplified signal and promoted promoter activity of NF-
ĸB; this results in profound TSLP production and release after transcription in comparison to 
each stimuli alone. 
 
3.3 MAST CELLS CONTRIBUTE TO TSLP PRODUCTION 
3.3.1 Murine skin produces TSLP in a mast cell tryptase and PAR-2-dependent 
mechanism ex vivo 
Since AD is mainly driven by TSLP overproduction and mast cells (MCs) have been 
associated with TSLP in various contexts121 such as MCs express highest levels of TSLPR as 




TSLP. Furthermore, MCs also enhance TSLP production by epithelial cells121,139. Based on 
literature and data produced in our group it was hypothesized that MCs act as intermediaries 
in the biological cascade promoting TSLP production, thereby boosting AD. To address the 
mechanisms behind MCs induced TSLP expression, murine skin was treated with purified 
MC mediators as well as MCs supernatant and the skin explant was studied ex vivo (Fig. 21). 
The results give strong evidence that MCs products specifically tryptase is crucial for the 
enhanced TSLP production (Fig. 21a) by murine skin explants, while histamine showed no 
impact on TSLP production (Fig. 21b). Murine skin explant produced excessive TSLP in 
response to tryptase in a dose dependent manner (Fig. 21a), while being neutral to histamine 
dose response (Fig. 21b). To study the mechanism behind the tryptase mediated exaggerated 
TSLP production by murine skin, it was investigated whether the murine skin was prone to 
enhanced TSLP production also upon exposure to MC supernatant, or whether the boost in 
TSLP production requires purified tryptase.  As expected, the presence of MC supernatant 
induced robust TSLP response in murine skin ex vivo. MC supernatant mediated enhanced 
TSLP induction was significantly inhibited by anti-mMCP6 antibody (Fig. 21c).  
As shown earlier, PAR-2 was involved in skin irritation-mediated TSLP production, therefore 
it was asked whether the mediators in the MC supernatant act via PAR-2. To investigate this, 
murine skin was exposed to the MC supernatants followed by anti-PAR-2 antibody. The 
results demonstrated that endogenous PAR-2 is essential for the MC supernatant mediated 
TSLP ex vivo, as anti-PAR-2 antibody drastically inhibited the TSLP production (Fig.21d). To 
validate the interplay between tryptase and PAR-2 during the induction of TSLP, the next 
complementary approach was to stimulate Wt and PAR-2-/- murine skin explants 



























Figure 21. Mast cells instruct murine skin to produce TSLP by a tryptase and PAR-2 
dependent mechanism. (a) Dose response of tryptase. (b) Histamine dose response. (c) After 
stimulation with mast cell supernatant, murine skin explants were incubated with anti-
mMCP6 antibody. gIgG served as isotype control. (d) Biopsies of murine skin after 
stimulation with mast cell supernatant were incubated with anti-PAR-2 antibody (mIgG2a 
served as isotype control). (a-d) Levels of TLSP were measured by ELISA after 12 h.  
The data, given as mean ± SEM, was analyzed using (a, b) Kruskall-Wallis with Dunn’s 
multiple comparison test or (c, d) paired t-test. mean ± SEM from 6-12 independent 








In line with the previous results, Wt murine skin explants resulted in robust TSLP production 
upon treatment with mMCP6, while PAR-2-/- skin explants were non-responsive to mMCP6 
stimulation (Fig. 22). Upon treatment with mMCP6 Wt skin explants produced significantly 
higher amount of TSLP compared to untreated Wt skin explants and to their counterpart PAR-
2-/- skin explants, while at baseline (unstimulated skin explants) there were no differences in 
TSLP production across the genotypes (Fig. 22).      
Figure 22. Exogenous mMCP6 induces TSLP in Wt skin explants, while PAR2 knockout 
explants are unresponsive. Skin biopsies from Wt and PAR-2 ko mice were treated with 
mMCP6 (10 ng/ml) for 12 h followed by measurement of TSLP levels in the supernatants 
using ELISA. The data is given as mean ± SEM from 6 independent experiments and 
analyzed using Kruskall-Wallis with Dunn’s multiple comparison test (**p<0.01). 
 
Taken together, the results show that MC tryptase is required for TSLP production in murine 





3.3.2 PAR-2 plays an important role in the compound 48/80-mediated induction of 
TSLP in vivo 
In order to test whether the ex vivo findings are transposable to the intact skin in vivo, a  
C48/80 (specific and potent MC degranulator) mediated MC degranulation model in Wt and 
PAR-2-/- genotypes was employed. The experimental scheme is shown in figure 8. C48/80 
mediated TSLP abundance in the skin was significantly less in PAR-2-/- murine skin 
compared to their Wt equivalent (Fig. 23a).    
The inhibition at mRNA expression level of TSLP was similar to protein expression of TSLP 
i.e. PAR-2-/- murine skin expressed significantly lower levels of TSLP transcript compared to 
their Wt counterpart upon C48/80 treatment (Fig. 23b).  
These results suggest that C48/80 mediated TSLP response results from activation of PAR-2 
signaling cascade. 










Figure 23.  PAR-2 knockout mice are protected from C48/80 mediated TSLP induction 
in vivo. Each mouse was intradermally injected with 100 µg of C48/80 (PBS served as 
control). (a) Skin lysate was prepared and TSLP was measured using ELISA. (b) TSLP 
mRNA expression in murine skin. Data are shown as mean ± SEM of 6 independent 





3.3.3 Intradermal C48/80-triggered TSLP production in murine skin in vivo depends 
on mMCP6 
To further confirm the presented ex vivo data and characterize the role of tryptase under in 
vivo conditions, a C48/80-mediated MC degranulation model after the neutralization of 
mMCP6 by using function-blocking antibody was employed. The experimental scheme is 
depicted in figure 9. As expected, intradermal C48/80 resulted in robust TSLP response 
compared to PBS treated group. TSLP abundance in the skin was significantly curtailed by 
intervention with anti-mMCP6 antibody (Fig. 24a), while interference with H1 and H4 
histamine receptor antagonists showed no impact on C48/80-mediated TSLP production 
(Appendix Fig. 30). These results suggest that the C48/80-mediated TSLP response takes 
place in a tryptase dependent manner and is independent of histamine.   
At the level of mRNA expression, TSLP transcripts resembled the protein data upon 
intradermal C48/80 treatment. In comparison to the PBS treated group C48/80 treated group 
resulted in profound increase in TSLP transcript levels and anti-mMCP6 antibody 
significantly inhibited C48/80-triggered TSLP mRNA expression (Fig. 24b). These results 
emphasize that C48/80-elicited TSLP induction depends on tryptase activated signaling 







Figure 24. Intradermal C48/80 induces TSLP in murine skin in vivo – dependence on 
mMCP-6. Each mouse was injected intradermal with 20 µg of anti-mMCP6 or gIgG. After 14 
h each mouse was intradermally injected with 100 µg of C48/80 (PBS served as control), and 
8 h after mice were sacrified. (a) Skin lysate were prepared and TSLP was measured using 
ELISA. (b) TSLP mRNA expression in murine skin. Data are shown as mean ± SEM of 6-9 
independent experiments (**p<0.01, ****p<0.0001) and was analyzed using Kruskall-Wallis 
with Dunn’s multiple comparison test. 
3.3.4  MC knockout mice are protected from C48/80 mediated TSLP induction ex vivo  
 Finally, to investigate the role of MCs in the induction of TSLP, a C48/80 mediated MC 
degranulation model was performed in the MC sufficient and MC knockout mice. The 
experimental scheme is shown in figure 9.  
  
Figure 25. C48/80 mediated TSLP induction in murine skin depend on mast cells ex vivo. 
(a) Beta-Hexosaminidase and (b) TSLP was measured in culture supernatant after incubation 
of murine skin explants with C48/80 for 1 and 12 h respectively, using enzyme-linked 
immunosorbent assay (ELISA). Untreated skin explants served as control.  
The data, given as mean ± SEM, from 4 independent experiments and was analyzed using 






As a positive control for MC degranulation, β-hexosaminidase was measured in the culture 
supernatant. C48/80-mediated β-hexosaminidase secretion was significantly less in MC-/- 
mice compared to MC sufficient mice (Fig. 25a), indicating strong degranulation of MCs in 
MC sufficient mice upon C48/80 treatment.   
C48/80-triggered a robust and significantly higher TSLP response in MC sufficient mice 
compared to MC-/- murine skin explants (Fig. 25b).    
Altogether, the presented results demonstrate that MC-/- mice are not prone to C48/80-
triggered TSLP production in murine skin.  
3.3.5 MC biomolecules trigger TSLP responses in human keratinocytes by tryptase in 
vitro        
To examine whether the findings in the murine system are transferable in humans, primary 
human KCs were stimulated with 0.1% whole MC lysate after immunoprecipitation 
(Appendix Fig. 31) of tryptase or in presence of  tryptase inhibitor nafamostat (NM) and 
TSLP levels were quantified in the culture supernatant. Under these experimental conditions, 
MC lysates induced robust TSLP production. Immunoprecipitation of MC lysate with anti-
tryptase antibody significantly decreased MC lysate triggered TSLP induction (Fig. 26a). 
Additionally, TSLP induction mediated by MC lysate was significantly inhibited in in the 
presence of NM (Fig. 26b).  
Collectively, MC derived biomolecules, specifically tryptase, activated pathways triggering 





Figure 26. Products from human skin mast cells induce TSLP in human keratinocytes 
by tryptase dependent pathway. (a) Human keratinocytes were incubated with mast cell 
lysate either with/without immunoprecipitation for tryptase or (b) in presence/absence of 
Nafamostat mesylate. Untreated cells served as control. TSLP was measured in cell culture 
supernatants after 24 h using ELISA. 
Data are shown as mean ± SEM of 8 independent experiments (**p<0.01) and was analyzed 
using Kruskall-Wallis with Dunn’s multiple comparison test. 
 
3.3.6 MC biomolecules act in concert with IL-1 to induce TSLP production by human 
keratinocytes 
As it was seen a synergistic effect of IL-1 and PAR-2 in the co-stimulation in vitro assays, it 
was speculated that MC biomolecules may also act in concert with IL-1 to trigger TSLP 
production by human KCs.  
Figure 27. IL-1 and human mast cell biomolecules co-operatively induce TSLP 
production by human keratinocytes. Human primary keratinocytes were incubated with 
lysate from human mast cells or IL-1α alone or in combination. Levels of TLSP were 




independent experiments (**p<0.01) and were analyzed using Kruskall-Wallis with Dunn’s 
multiple comparison test. 
Given the fact that tryptase acts by activating PAR-2 pathway, it is highly likely that similar 
co-operative induction of TSLP upon co-stimulation with IL-1 and MC lysate will be found. 
To test this human primary KCs were stimulated with IL-1 and MC lysate individually as well 
as combined. As expected, a robust induction in TSLP production by KCs when co-stimulated 
with IL-1 and MC lysate compared to each individual stimuli was found (Fig. 27). These 
results suggest that different signaling pathways activated by respective stimuli (MC lysate 
mediated activation of PAR-2 and exogenous IL-1 mediated activation of IL-1 signaling 
cascade) act in concerted fashion to induce profound TSLP response. 
 
Figure 28. Graphical depiction of mast cell and keratinocyte interaction in the 
production of TSLP. Skin barrier disruption leads to TSLP production by KCs, which 
further act on the dermal MCs and enhance their survival. Upon degranulation of MCs by IgE 
mediated receptor crosslinking or by activation of MRGPRx2 receptor pathway, MC 
mediators specifically tryptase in turn act on epidermal KCs by PAR-2 mediated pathway to 












TSLP is a well-known pro-inflammatory cytokine which plays a crucial role in inflammatory 
diseases41,140. It is highly upregulated in keratinocytes (KCs) upon skin barrier 
perturbation36,141 and considered to be the initiator of AD. Murine skin overexpressing TSLP 
has been reported to develop spontaneous dermatitis alike to characteristics of human 
AD34,106. Despite the significant advances in the understanding of the role of TSLP in the 
development of Th2-mediated inflammation in skin and allergic diseases, the understanding 
of the regulatory mechanisms of endogenous TSLP production in skin inflammation and 
particularly in AD are still in its infancy.  
 
In this thesis, the role of TSLP in the progression of AD and mechanisms behind skin-
irritation as well as mast cells mediators mediated TSLP production was investigated. 
Additional aim was to better understand the role of endogenous TNF under the micro-milieu 
of AD and in relation to TSLPR in vivo.. Furthermore, in recent studies MCs were emerging 
as another important component of AD pathogenesis. MCs have been reported to be 
increased in the lesional skin of AD in case of both human as well as mice.142 To examine the 
contribution of MCs in the induction of TSLP production by human KCs and in murine skin 
MC degranulation model in vivo as well as ex vivo was employed. Furthermore, MC lysate 
and purified MC mediators were analyzed in more detail ex vivo and in vitro.  
4.1 TNF-/- MICE DEVELOP AGGRAVATED AD WHICH COULD BE RESCUED 
BY THE ABSENSE OF TSLPR EXPRESSION  
AD is a complex, chronic and pruritic inflammatory skin disease. Immune dysregulation in 
combination with epidermal barrier defect cause development of AD.143 Beside 
immunological components, pharmacological abnormalities are critical in the disease 
development and progression.22 
 
TNF-α is a pleiotropic cytokines crucial for host defense and known for its ability to trigger 
inflammatory response concurrently with an immune dysregulation.144,145 Anti-TNF 
therapeutics for autoimmune disorders like inflammatory bowel disease, psoriasis and 
rheumatoid arthritis are authorized and proving effective with rather few side-effects146. Most 
common therapies in use for disrupting the TNF function in autoimmune diseases are 
monoclonal antibodies, adalimumab as well as infliximab, in addition to the soluble receptor 




clear. Based on literature analysis, there are more indications of positive rather than negative 
impact of TNF on AD. Takahashi et al. (1992) reported that TNF-α was decreased in PBMCs 
derived from AD patients in comparison to healthy individuals.149 In alignment, it was 
observed that the expression levels of TNF-α, IL-1β and IFN-γ were reduced in the skin 
samples of AD patients compared to skin samples obtained from psoriasis patients.150 
Furthermore, TNF-α producing dermal inflammatory dendritic cells (DCs) were reported to 
be lower in the skin of AD patients compared to skin of psoriasis patients.151 The 
epidemiological studies from our institution as well as from different clinics provided the 
most noticeable evidence, which stated the manifestation of symptoms similar to AD due to 
side effects of anti-TNF therapy.152-156 These observations hint towards a protective role of 
TNF in the framework of AD, and previously in our group we had seen that TNF deficient 
mice developed exaggerated AD, providing experimental evidence.216  
 
TSLP is a well-known important proinflammatory cytokine  in AD and asthma.157 Increased 
TSLP expression has been reported in lesional skin of AD patients but not in contact 
dermatitis, induced by nickel.106 TSLP is a member of IL-2 family and IL-7 type of cytokine. 
It can act on DCs and promote the Th2 immune response by differentiation and recruitment 
of Th2 cells. Naïve CD4+ cells can also be directly targeted by TSLP to induce proliferation, 
in response to antigen.114 It has been shown that epithelial cell-derived TSLP can activate 
DCs, T cells and MCs.130 TSLP overexpression in murine skin resulted in the development of 
spontaneous dermatitis.34,106 In alignment with the literature, TSLP was significantly 
upregulated in AD skin of TNF-/- mice and correlated with disease severity. TNF-α is known 
to induce TSLP expression. Brandt et al. (2011) reported that human skin explants produce 
higher amount of TSLP, when stimulated with a combination of TNF-α, IL-1α and Th2 
cytokines, but not individually.31 Complementary findings were reported from KC 
cultures.158,159  To understand why TNF-/- mice exhibit aggravated AD and weather TSLP is 
prime reason for AD development in these mice, a murine model was employed. To define 
the underlying mechanisms, an AD mouse model was performed in Wt, TNF-/- ,TSLPR-/- 
and  TNF-/- TSLPR-/- double knockout mice to mimic the human AD scenario. The results 
clearly indicate that TNF-α plays a protective role against development of AD as reported in 
the literature. Significant worsening of the severity of AD-like lesions in the TNF-/- mice in 
comparison to Wt, TSLPR-/- and TNF-/-TSLPR-/- double knock out mice was observed. The 
analysis of the severity in the AD model was performed based on SCORAD score, a tool to 




double knockout mice were protected from development of AD symptoms suggesting TSLP 
as another essential factor in the development of AD. Previously, it has been shown that MC 
but not the T cells were enhanced in AD lesions of TNF-/- mice and correlated with disease 
severity as well as to increased mRNA levels of TSLP in lesional skin.216 It was shown by 
Han et al. that TSLP was able to induce the proliferation and differentiation of MCs as well 
as the number of MC was significantly higher in different organs of Wt mice in comparison 
to TSLP-deficient mice.161                             
         
4.2 SKIN IRRITATION-MEDIATED TSLP PRODUCTION DEPENDS ON IL-1 
AND PAR-2 PATHWAYS   
TSLP is subject to several studies and well-known as an important factor of allergic disorders 
in the lung, skin, and gut organs.41,140 TSLP is abundantly expressed in KCs when the skin 
barrier is disrupted by genetic intervention.36,141,162-165 Skin barrier compromised by irritation 
triggers TSLP response in similar manner, supporting a further connection between damaged 
skin integrity and TSLP expression.20,117,121,122 Thus TSLP can be considered as initial and 
sensitive signal of skin barrier disruption of various sorts, making it necessary to explore the 
molecular mechanism of its regulation.   
How skin irritation-mediated barrier disruption leads to TSLP production is an open question. 
Separately from limited contribution of IL-120, the mediators and underlying mechanisms are 
unclear in spite of  the regular physical insults to which the skin is continually exposed in 
daily life and the applicability to the itch-scratch cycle to AD manifestation.    
The role of IL-1 in skin inflammation is well-established. Indeed, both IL-1α and IL-1β, 
founding members of the family, are key coordinators to induce clinically distinct signs of 
skin inflammation by predominantly upregulating the expression of the entire range of 
inflammatory genes during sterile inflammation, skin infections and other abuses.166-168 In 
response to skin injury KCs release pre-formed IL-1α169 which in turn act as alarmin to 
recruit T cells to further enhance IL-1 (e.g. by inducing IL-1β expression in KCs).170,171 IL-1α 
and IL-1β by acting alone or in combination with other pro-inflammatory cytokines sustain 
the inflammatory micro-milieu by further supporting the cytokine production by immune 
cells in a feed-forward loop.170,172-174  
 Beside its well-known contribution to skin inflammation, IL-1 played a role in skin 




inhibition yielded in 20-50%  decrease in TSLP production, relaying on the setup.20 Thus, the 
question arose what alternate pathways may be activated in the irritated skin to induce TSLP 
production. PAR-2 turned out to be a major route, which can be activated upon barrier 
disruption. 
Regardless of the reproduction of the cross-talk between IL-1 and PAR-2 in human and 
mouse, there were also discrepancies. In the mouse activation of PAR-2 alone was able to 
induce TSLP, and the neutralization of endogenous PAR-2 resulted in reversal of TSLP 
induction mediated by barrier disruption. This is of importance given the fact that efficacy of 
IL-1 to induce TSLP was extensively weaker in comparison to human20, so that PAR-2 
triggering on its own may adopt a major role in the mouse. However, and a key finding of 
this study, it was the simultaneous activation of IL-1 and PAR-2 cascades that facilitated 
robust induction of TSLP in both species.   
The presented findings indicate that under the conditions of subclinical inflammation or mild 
skin irritation, as shown by minute concentrations of IL-1, could be incited measurable TSLP 
production when PAR-2 is concomitantly activated. The proteases to achieve this may be 
endogenous but also exogenous and would by themselves result in moderate TSLP induction 
but would be emancipated to do so in the occupancy of low levels of IL-1. In fact, various 
activated proteases in the skin habitat can lead to activation of endogenous PAR-2, including 
kallikreins 5 and 14.92,175-177 In other conditions, the proteases to activate PAR-2 may be 
exogenic. Noteworthy, several allergens have protease activity, and presumably activate 
PAR-2 on KCs.178-180 Therefore, PAR-2 is reckoned as the major sensor of  proteases in the 
skin with numerous pathophysiological implications.181 
Despite the importance of both signaling cascades to skin biology in health and disease, there 
are strangely no studies addressing their likely cooperation in the skin, and only few reports 
altogether. Chhabra et al. (2007) reported in airway smooth muscle cells, enhanced GM-CSF 
production by stimulation with combination of protease and IL-1 in comparison to IL-1 
alone, but this apparently proceeded via a mechanism independent of PAR-2.182 Fyfe et al. 
(2005) on the other hand, showed synergistic effect on IL-8 production by IL-1 and PAR-2, 
in the Caco-2 adenocarcinoma line.183 To the best of our knowledge the last mentioned is the 
only report that provided evidence for cooperation between IL-1 and PAR-2. 
The level at which merging of IL-1 and PAR-2 occur to increase TSLP production was 




PAR-2 in addition to well-known IL-1 mediated activation. It has been reported for multiples 
cell lines that PAR-2 triggering leads to biologically significant NF-κB pathway 
activation.180,184-188  
TSLP expression majorly regulated by NF-κB and four consensus NF-κB binding sites (BSs) 
have been reported in its ≈4-kb-promoter region.136,137  Stimulation with IL-1 leads to 
recruitment of NF-κB to two of these BSs present at -0.37 kb and -3.8 kb upstream of 
transcription start site, respectively.137   
It was found that upon stimulation with IL-1 alone, NF-κB was recruited to both BSs while 
treatment with PAR-2-Ag alone, had no measurable impact. Interestingly the combination of 
PAR-2-Ag with IL-1 strongly enhanced the binding to BS4, the major site associated with 
activation of TSLP promoter. The same phenomena was observed even at low IL-1 
concentrations.  
Probably, the two functionally active NF-κB BSs differently contribute to the regulation of 
TSLP in an organ specific manner, e.g. between gut and skin tissue.189  It’s hypothesized that 
the TSLP expression at baseline and upon induction is differentially regulated by these two 
BSs.190 Indeed, IL-1 (with or without PAR-2 activation) is more potent in recruiting NF-κB at 
BS4 in comparison to BS1, the latter rather similar to housekeeping-like functions. Increased 
NF-κB recruitment was reflected by enhanced activity of TSLP promoter upon co-stimulation 
with IL-1 and PAR-2-Ag, suggesting that binding represented the efficiency of transcriptional 
output.  
Together, our results indicate that increased binding of NF-κB to its BSs regulate the 
collaboration between IL-1 and PAR-2.  
The findings of this study and the sequential events are graphically depicted in figure 20. 
 
4.3 MAST CELLS INSTRUCT KERATINOCYTES TO PRODUCE TSLP 
Based on previous studies that TSLP is the initiator of AD under TNF deficiency. Moreover, 
enhanced number of MCs in lesional skin of TNF-/- mice and its strong correlation with the 
severity of AD indicates that MCs are playing a crucial role in the induction of TSLP.216 On 
this background, it was presumed that MCs are upstream of TSLP in this scenario. MCs have 
been associated with TSLP under different conditions such as they are shown to produce 




increase TSLP production by epithelial cells.139 Further, as shown earlier, PAR-2 plays an 
important role in the induction of TSLP. It has been known that MCs mediators can activate 
PAR-2.192 Based on this background, the underlying mechanism behind the cross talk 
between MCs and KCs in TSLP production was investigated.  
 
For this purpose, the effect of MCs supernatants/lysates and mast cell mediators was studied 
in the context of the induction of TSLP production. Different experimental approaches with 
MCs, skin explants and KCs were used for that purpose.   
   
MCs degranulate upon stimulation with anti-IgE as a result of crosslinking of the FcεRI, 
which eventually leads to the release of MC mediators such as histamine and proteases.193,194 
As Total protein content of MCs consist of between 30-50% MC proteases.195,196 We selected 
tryptase and histamine, as they are the two most abundant MC mediators, for their ability to 
induce the production of TSLP. In order to examine the role of MC mediators that may act on 
KCs in the skin to induce TSLP production, skin explants were incubated with the purified 
MC mediators or supernatants of resting MCs ex vivo. 
. 
Histamine is believed to be the key factor in the communication between MCs and KCs.69,197 
Human KCs and organotypic skin models showed that histamine downregulates the 
expression of differentiation related proteins like filagrin, loricrin and Keratin in addition to 
desmosomal and tight junction proteins.198 These data indicate that activation of MCs and 
release of histamine contribute to the initiation of AD by promoting skin barrier defects.198 
Additionally, histamine is considered as one of the prominent pruritogenic mediators. Itch is 
an integral part of AD, although histamine 1 receptor (H1R) antagonist was not able to 
ameliorate the itch in lesional skin of AD patients.199 However it has been reported that 
simultaneous treatment with a H1R and histamine 4 receptor (H4R) antagonists showed anti-
pruritogenic and anti-inflammatory effects, in a model of chronic allergic dermatitis in 
NC/Nga mice.200      
 
Based on this literature and presented data, it seems clear that one of the major mast cell 
mediator does not appear to play a role for increased TSLP levels. Intriguingly, upon 
stimulation of skin biopsies with supernatants from resting MCs, TSLP levels were 
significantly increased. These data suggest that some of the MCs mediators other than 





However, the supernatant obtained from unstimulated resting MCs consists of only the 
mediators released spontaneously (e.g. by piecemeal degranulation201), mediators associated 
with granules are at lower concentrations in the supernatants from unstimulated MCs.202       
Interestingly, skin explants exposed to tryptase produced significantly higher amounts of 
TSLP in a dose dependent manner. On the other hand, histamine failed to enhance TSLP 
production on performing the dose response, as no single concentration of histamine resulted 
in enhanced  TSLP production compared to untreated skin biopsies.  
Therefore, tryptase was tested next as a possible elicitor of TSLP. Tryptase has been shown 
to induce scratching behavior by activating PAR-258,203 and associated with severity of 
AD.204 Thus, it was investigated whether tryptase act via PAR-2 signaling cascade in skin to 
trigger TSLP production. PAR-2 turned out to be an essential route, which can be activated 
by tryptase. mMCP6 is the mouse analog of human β-tryptase, which was indeed resulted in 
enhanced TSLP production.  
To investigate the role of PAR-2 mediated TSLP induction in the skin by tryptase, different 
approaches were performed. Tryptase, histamine as well as MCs supernatants/lysates were 
used to induce TSLP production. In one experimental model tryptase resulting from MCs 
supernatants and endogenous PAR-2 were blocked using anti-PAR-2 and anti-mMCP6 
antibodies. In a second approach, mMCP6 was exogenously applied to activate PAR-2 
pathway both in Wt and PAR-2 knockout mice. In the first scenario, we found inhibition of 
MCs supernatants mediated TSLP induction by anti-mMCP6 and anti-PAR-2 antibodies was 
found. In exogenous setting, induction of tryptase mediated PAR-2 dependent induction of 
TSLP, verifying our previous findings, was seen. To delineate whether degranulation of the 
MCs induce TSLP production in PAR-2 dependent manner in vivo, it was confirmed that 
C48/80 (a potent MC degranulator57,58)-mediated degranulation of MCs induce robust TSLP 
production in Wt mice compared to their counterpart PAR-2 knockout mice. This points 
towards interaction between MCs mediators and KCs through activation of PAR-2 also under 
in vivo conditions.  
Next the role of MCs mediators in the in vivo settings was investigated. Intradermal 
administration of anti-mMCP6 antibodies resulted in a significant reduction in the C48/80 
induced TSLP production, in comparison to isotype control. In contrast, intervention with 
H1R and H4R showed no inhibition. These data confirm the ex vivo findings that tryptase but 




explore the role of MCs in the induction of TSLP MC deficient mice were used. Skin 
biopsies from control mice and MC deficient mice were incubated in presence of C48/80. As 
expected, MC deficient mice produced significantly less amount of TSLP in comparison to 
the control mice. These data suggest that MC instruct KCs to produce enhanced TSLP levels 
through activation of PAR-2 by tryptase.  
To answer the question whether the findings in murine system apply to humans whole MCs 
lysates was used to stimulate human primary KCs. Interestingly, it turned out that MCs 
lysates were able to induce TSLP production in a tryptase dependent manner, as 
immunoprecipitation (IP) of tryptase lead to significant inhibition of MCs lysate-induced 
production of TSLP. As a complimentary approach to validate the role of MCs tryptase in 
inducing TSLP response nafamostat (potent tryptase inhibitor) was employed. Clearly, 
incubation with nafamostat resulted in significant reduction in MCs lysates mediated 
induction of TSLP expression. Further, in alignment with the previous findings of PAR-2 and 
IL-1 mediated cooperative TSLP induction, co-stimulation of KCs with MCs lysates and IL-
1α resulted in robust TSLP induction. These data suggest typtase mediated activation of 
PAR-2 act in concert with IL-1 to induce TSLP expression by KCs.    
Based on presented data it appears to be clear that tryptase is the main mediator from the 
MCs that results in triggering a robust TSLP production by both murine skin and human 
KCs. In support, it was showed by Thakurdas et al. (2007) that mMCP6-/- mice had a 
decreased capability to fight K. pneumonia infections, indicating an important immune 
protective role of mMCP6 in microbial/bacterial infections. mMCP6 was not found essential 
for the maturation, retention and migration of MC-committed progenitors.205 It was reported 
that lesional skin of AD patients express highly upregulated tryptase like enzymes in the 
stratum cornneum.206 Furthermore, elevated tryptase levels were observed in MCs from AD 
patients.207 However, two studies have analyzed tryptase serum levels for suitability as a 
serum marker for AD, but reported no correlation between severity of AD and levels of 
tryptase in the serum.208,209 In contrast, recently Sahiner et.al. (2018) reported serum basal 
tryptase levels are associated with disease severity and atopy.204 Tryptase has been associated 
with AD mediated itch and scratching.58,210 Recently, it was reported that MCs degranulation 
and PAR-2 activation are involved in scratching behavior and the authors reported similar 
increase in TSLP production in their AD model which further supports our findings.211  
Additionally, Tomoaki Ando et al. (2014) have reported in Plcb3-/- mice that MCs but not 





The recently published first body-wide expression atlas for humans (FANTOM5), revealed 
that MCs express highest levels of the TSLPR (CRLF2) of all cells in the body.213,214 In 
agreement with receptor expression TSLP has been shown to increase MC survival.161 
(Hazzan et al. Submitted). Together with recent achievements in human lung MCs, which 
also reported functional TSLPR in these cells.215 These findings fit the concept that MCs 
might be highly significant targets of the cytokine whose production they promote.  
 
Collectively, MCs and KCs form an intricate cellular network unit in pathophysiology of 
TSLP by acting as regulator, producer and targets of TSLP. MCs induce TSLP by their 
proteases, specifically tryptase regulates TSLP production by KCs in a PAR-2 dependent 
manner. Furthermore, combined stimulation with MCs lysates and IL-1 resulted in enhanced 
TSLP response by KCs. TSLP then acts back on MCs favoring survival161 (Hazzan et. al. 
Submitted), thereby creating a positive feed-forward loop (Fig. 28). Histamine failed to 
modulate the TSLP production, in contrast mMCP6 significantly induced TSLP expression 
by KCs in the skin biopsies, suggesting that MCs mediator tryptase is involved in instructing 
KCs by activating PAR-2 to produce TSLP.           
4.4 CONCLUSION AND OUTLOOK     
The skin is largest organ of the body and forms part of the first line of defense against 
pathogens or external insults. The epidermis is the outermost layer of the skin and provides 
the anatomical structure to form the skin barrier. Any kind of impairment to the skin barrier 
homeostasis triggers an inflammatory response which may lead to the development of skin 
diseases. In this thesis mechanisms of TSLP regulation either by barrier disruption or by MCs 
mediators have been investigated.  
The results presented provide newer insights into the role of IL-1-PAR-2 pathways 
interaction in regulating TSLP in the skin. The data shown revealed that upon barrier 
disruption or irritant exposure keratinocytes rapidly produce robust TSLP. Moreover 
disturbances in skin homeostasis by mild physical irritation or upon exposure to MCs 
mediators resulted in induction of TSLP production. These findings indicate that TSLP in the 
skin acts as an alarmin, upon encounter to any kind of skin injury. The mechanistic analysis 
demonstrated that mild skin irritation-mediated TSLP induction results from co-activation of 




upon skin perturbation, was partially contributed in tape stripping-mediated TSLP production 
and PAR-2 turned out to be another important pathway involved in TSLP production. Using 
the ChIP and functional reporter assay it was demonstrated that the signals from IL-1-and-
PAR-2 pathway converse on the TSLP promoter in human keratinocytes. To this end, skin 
biopsies, 3D keratinocyte cultures and co-culture of mast cells with keratinocytes will be 
employed. Furthermore, potential mediators and/or signaling pathways will be studied using 
in vivo mouse models. Different antibodies, agonist, antagonists and inhibitors will be used to 
treat the skin biopsies and cell cultures.                
 
To better understand the importance of TSLP in absence of TNF in the development of AD, 
mouse model of dermatitis was performed. TNF-/- mice developed high AD severity and the 
severity was abolished in TSLPR-/-TNF-/- double knockout mice, similar to TSLPR-/- mice. 
Up to this point, mast cell number is significantly increased in the skin lesions of TNF-/- 
mice, indicating the involvement of mast cells in this AD model.216 Further, analysis of these 
mice will include histological examination of skin, study of single cell types and factors in 
serum in different genotypes. To get better insight in the role of mast cells these data should 
be confirmed using TNF-/-MC-/- double knockout mice to prove the role of mast cells under 
the deficiency of TNF in AD progression.  
 
As previous findings indicated the involvement of mast cells in the development of AD, it 
was asked whether mast cells can directly induce TSLP production as they have been 
reported to produce TSLP191 or whether they can direct keratinocytes to TSLP during 
promotion of AD, as they are shown to instruct cells of epithelia to enhance TSLP 
production.139 It was observed previously that bone marrow derived mast cells were not able 
to produce TSLP either after activation with anti-IgE alone or in combination with other 
cytokines.216 Based on these findings it was hypothesized that mast cells can instruct 
keratinocytes to produce TSLP. To verify this hypothesis, skin biopsies were stimulated with 
purified mast cell mediators and resting mast cell supernatants. Tryptase as well as 
supernatants from resting mast cells induced significant TSLP production while histamine 
failed to do so. Further, to investigate the mechanism behind tryptase-mediated TSLP 
induction skin explants from PAR-2 knockout mice were stimulated using mMCP6. 
Surprisingly, only Wt murine skin explants responded to mMCP6 treatment and produced 
significantly high levels of TSLP, PAR-2 knockout skin explants failed to respond.  These 




C48/80 mediated mast cell degranulation in vivo model was used, anti-mMCP6 in addition to 
H1R and H4R antagonists were employed. It was observed that anti-mMCP6 antibody 
inhibited C48/80 mediated TSLP induction while H1R and H4R antagonists had no effects. 
In the skin of PAR-2 knockout mice found significantly less TSLP expression was found 
compared to Wt mice upon application of C48/80.  
 
To better understand the role of mast cells in the induction of TSLP, mast cell knockout mice 
were used. As expected, significantly less TSLP in the culture supernatants of mast cell 
knockout mice in response to C48/80 treatment was found. After observing the involvement 
of tryptase in the induction of TSLP with several approaches, human primary keratinocytes 
were investigated. Primary human keratinocytes were stimulated with lysates of mast cells, to 
ensure that the effects on TSLP production were from tryptase immunoprecipitation of 
tryptase on whole mast cell lysates was performed. Additionally, nafamostat was used to 
confirm the findings. In the presence of immunoprecipitated lysates or nafamostat 
keratinocytes did not produce enhanced TSLP in comparison to cell treated with mast cells 
lysates without immunoprecipitation or in the absence of nafamostat. Finally, after 
investigating the role of tryptase and PAR-2 in the TSLP production, it was asked if mast cell 
lysate can act in co-operation of low levels of IL-1, as seen before with PAR-2-Ag. To test 
this stimulated the human keratinocytes were stimulated with mast cells lysate individually as 
well as in combination with low levels of IL-1 (2 ng/ml) and found the co-stimulation 
resulted in highest increase in the induction of TSLP.  
 
Inflammation and irritation of skin is an intricate system which involves the interaction of 
resident skin cells like keratinocytes and mast cells. Both IL-1 and PAR-2 contribute to this 
interaction in this scenario with a significant magnitude. Mouse skin models can be utilized 
to gain further insights into the mechanism of this complex network by implementing 
knockout mice models and by selective or collective targeting of major effector mediators in 
appropriate disease models. 
 
In summary these studies reveal an important role of skin irritation and mast cells mediators 
in the production of TSLP and provide insights into how PAR-2 and IL-1 pathways promote 
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Appendix Figure 29. Interleukin (IL)-1 results in the recruitment of NF-ĸB to the IL-8 
promoter. NF-ĸB was recruited to the NF-ĸB binding site in the IL-8 promoter region in 
response to stimulation with IL-1α (100 ng/ml). Used as positive control for the anti-NF-ĸB 





Appendix Figure 30. Intradermal C48/80 induces TSLP in murine skin in vivo – 
independent of H1 and H4 receptors. Each mouse was given oral gavage with either 
desloratadin (H1 receptor antagonist) or JNJ maleate (H4 receptor antagonist) or PBS. After 
14 h each mouse was intradermally injected with 100 µg of C48/80 (PBS served as control), 
and 8 h after mice were sacrified. Skin lysatse were prepared and TSLP was measured using 









           
 
 
Appendix Figure 31. Immunoprecipitation (IP) of tryptase.  
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